Cancer-associated myositis

Clinical features and prognostic signs

A. Ponyi, T. Constantin, M. Garami, C. András, Béla Tállai, Andrea Váncsa, L. Gergely, K. Dankó

Research output: Contribution to journalArticle

95 Citations (Scopus)

Abstract

Idiopathic inflammatory myositis is characterized by progressive weakness of the proximal muscles. There is a higher risk of malignancy than in the normal population. The aim of this study was to evaluate the frequency of malignancy among 251 myositis patients. We also compared clinical and immunological characteristics of cancer-associated myositis with primary myositis. There were no malignancies among polymyositis, overlap, or juvenile myositis patients. Twenty-two of ninety dermatomyositis patients also had a malignant disease. Patients with cancer-associated dermatomyositis were significantly older than primary myositis patients and had more severe cutaneous and muscle symptoms. Dysphagia and diaphragmatic involvement were more frequent among cancer-associated patients, while extramuscular features were less frequent. After successful treatment of the malignancy, we were able to manage myositis symptoms. One-year survival rate was significantly better in primary dermatomyositis patients. The subset of cancer-associated myositis differs from primary myositis in many aspects of its clinical and immunological features. Prognosis and life expectancy in cancer-associated myositis patients is determined by the underlying malignant disease. Therefore, age- and sex-specific examinations for detection of an underlying malignancy are important in the management of patients with dermatomyositis.

Original languageEnglish
Pages (from-to)64-71
Number of pages8
JournalAnnals of the New York Academy of Sciences
Volume1051
DOIs
Publication statusPublished - 2005

Fingerprint

Myositis
Muscle
Dermatomyositis
Neoplasms
Cancer
Polymyositis
Muscle Weakness
Deglutition Disorders
Life Expectancy
Survival Rate
Muscles
Skin

Keywords

  • Cancer
  • Clinical features
  • Dermatomyositis
  • Prognostic signs
  • Survival

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

@article{b929c4fb628e40028b05588d1c5dfbf1,
title = "Cancer-associated myositis: Clinical features and prognostic signs",
abstract = "Idiopathic inflammatory myositis is characterized by progressive weakness of the proximal muscles. There is a higher risk of malignancy than in the normal population. The aim of this study was to evaluate the frequency of malignancy among 251 myositis patients. We also compared clinical and immunological characteristics of cancer-associated myositis with primary myositis. There were no malignancies among polymyositis, overlap, or juvenile myositis patients. Twenty-two of ninety dermatomyositis patients also had a malignant disease. Patients with cancer-associated dermatomyositis were significantly older than primary myositis patients and had more severe cutaneous and muscle symptoms. Dysphagia and diaphragmatic involvement were more frequent among cancer-associated patients, while extramuscular features were less frequent. After successful treatment of the malignancy, we were able to manage myositis symptoms. One-year survival rate was significantly better in primary dermatomyositis patients. The subset of cancer-associated myositis differs from primary myositis in many aspects of its clinical and immunological features. Prognosis and life expectancy in cancer-associated myositis patients is determined by the underlying malignant disease. Therefore, age- and sex-specific examinations for detection of an underlying malignancy are important in the management of patients with dermatomyositis.",
keywords = "Cancer, Clinical features, Dermatomyositis, Prognostic signs, Survival",
author = "A. Ponyi and T. Constantin and M. Garami and C. Andr{\'a}s and B{\'e}la T{\'a}llai and Andrea V{\'a}ncsa and L. Gergely and K. Dank{\'o}",
year = "2005",
doi = "10.1196/annals.1361.047",
language = "English",
volume = "1051",
pages = "64--71",
journal = "Annals of the New York Academy of Sciences",
issn = "0077-8923",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Cancer-associated myositis

T2 - Clinical features and prognostic signs

AU - Ponyi, A.

AU - Constantin, T.

AU - Garami, M.

AU - András, C.

AU - Tállai, Béla

AU - Váncsa, Andrea

AU - Gergely, L.

AU - Dankó, K.

PY - 2005

Y1 - 2005

N2 - Idiopathic inflammatory myositis is characterized by progressive weakness of the proximal muscles. There is a higher risk of malignancy than in the normal population. The aim of this study was to evaluate the frequency of malignancy among 251 myositis patients. We also compared clinical and immunological characteristics of cancer-associated myositis with primary myositis. There were no malignancies among polymyositis, overlap, or juvenile myositis patients. Twenty-two of ninety dermatomyositis patients also had a malignant disease. Patients with cancer-associated dermatomyositis were significantly older than primary myositis patients and had more severe cutaneous and muscle symptoms. Dysphagia and diaphragmatic involvement were more frequent among cancer-associated patients, while extramuscular features were less frequent. After successful treatment of the malignancy, we were able to manage myositis symptoms. One-year survival rate was significantly better in primary dermatomyositis patients. The subset of cancer-associated myositis differs from primary myositis in many aspects of its clinical and immunological features. Prognosis and life expectancy in cancer-associated myositis patients is determined by the underlying malignant disease. Therefore, age- and sex-specific examinations for detection of an underlying malignancy are important in the management of patients with dermatomyositis.

AB - Idiopathic inflammatory myositis is characterized by progressive weakness of the proximal muscles. There is a higher risk of malignancy than in the normal population. The aim of this study was to evaluate the frequency of malignancy among 251 myositis patients. We also compared clinical and immunological characteristics of cancer-associated myositis with primary myositis. There were no malignancies among polymyositis, overlap, or juvenile myositis patients. Twenty-two of ninety dermatomyositis patients also had a malignant disease. Patients with cancer-associated dermatomyositis were significantly older than primary myositis patients and had more severe cutaneous and muscle symptoms. Dysphagia and diaphragmatic involvement were more frequent among cancer-associated patients, while extramuscular features were less frequent. After successful treatment of the malignancy, we were able to manage myositis symptoms. One-year survival rate was significantly better in primary dermatomyositis patients. The subset of cancer-associated myositis differs from primary myositis in many aspects of its clinical and immunological features. Prognosis and life expectancy in cancer-associated myositis patients is determined by the underlying malignant disease. Therefore, age- and sex-specific examinations for detection of an underlying malignancy are important in the management of patients with dermatomyositis.

KW - Cancer

KW - Clinical features

KW - Dermatomyositis

KW - Prognostic signs

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=25444481810&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=25444481810&partnerID=8YFLogxK

U2 - 10.1196/annals.1361.047

DO - 10.1196/annals.1361.047

M3 - Article

VL - 1051

SP - 64

EP - 71

JO - Annals of the New York Academy of Sciences

JF - Annals of the New York Academy of Sciences

SN - 0077-8923

ER -